Biofrontera Operating Margin from 2010 to 2024
| BFRI Stock | USD 0.99 0.03 2.94% |
Check Biofrontera financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biofrontera's main balance sheet or income statement drivers, such as Tax Provision of 33 K, Interest Income of 90.6 K or Depreciation And Amortization of 1.5 M, as well as many indicators such as Price To Sales Ratio of 0.12, Dividend Yield of 0.0 or PTB Ratio of 0.85. Biofrontera financial statements analysis is a perfect complement when working with Biofrontera Valuation or Volatility modules.
Biofrontera | Operating Margin |
Latest Biofrontera's Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Biofrontera over the last few years. It is Biofrontera's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biofrontera's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (0.65) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Biofrontera Operating Margin Regression Statistics
| Arithmetic Mean | (0.62) | |
| Coefficient Of Variation | (23.28) | |
| Mean Deviation | 0.1 | |
| Median | (0.57) | |
| Standard Deviation | 0.15 | |
| Sample Variance | 0.02 | |
| Range | 0.6305 | |
| R-Value | (0.46) | |
| Mean Square Error | 0.02 | |
| R-Squared | 0.21 | |
| Significance | 0.09 | |
| Slope | (0.01) | |
| Total Sum of Squares | 0.30 |
Biofrontera Operating Margin History
About Biofrontera Financial Statements
Investors use fundamental indicators, such as Biofrontera's Operating Margin, to determine how well the company is positioned to perform in the future. Although Biofrontera's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. Biofrontera operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 69 people.
Currently Active Assets on Macroaxis
When determining whether Biofrontera offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biofrontera's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biofrontera Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biofrontera Stock:Check out the analysis of Biofrontera Correlation against competitors. For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biofrontera. If investors know Biofrontera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biofrontera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.16 | Revenue Per Share 11.573 | Quarterly Revenue Growth 0.34 | Return On Assets (0.40) | Return On Equity (1.49) |
The market value of Biofrontera is measured differently than its book value, which is the value of Biofrontera that is recorded on the company's balance sheet. Investors also form their own opinion of Biofrontera's value that differs from its market value or its book value, called intrinsic value, which is Biofrontera's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biofrontera's market value can be influenced by many factors that don't directly affect Biofrontera's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biofrontera's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biofrontera is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biofrontera's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.